Christine Erikstrup Hallgreen

Christine Erikstrup Hallgreen

Associate Professor

Member of:

    ORCID: 0000-0002-7916-3915

    Publication year:
    All
    11 - 20 out of 36Page size: 10
    Sort by: Title
    1. Published

      How and Why to Involve Patients in Drug Development: Perspectives from the Pharmaceutical Industry, Regulatory Authorities and Patient Organizations

      Hansen, M. B., Nørgaard, Lotte Stig & Hallgreen, Christine Erikstrup, 2020, In: Therapeutic Innovation & Regulatory Science. 54, p. 577-585 9 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    2. Published

      How to Measure the Impact of Pharmacovigilance Activities on Public Health?

      Gardarsdottir, H., Kant, A., De Bruin, M. L., Hallgreen, Christine Erikstrup, Dal Pan, G. & Way, D., Aug 2017, p. 31-31.

      Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

    3. Published

      Hydroxysine initiation following drug safety advisories on cardiac arrhythmias in the UK and Canada: A longitudinal cohort study

      Morrow, R., Mintzes, B., Souverein, P., Hallgreen, Christine Erikstrup, Ahmed, B., Roughead, E., De Bruin, M. L., Kristiansen, S., Lexchin, J., Kemp-Casey, A., Sketris, I., Mangin, D., Pearson, S., Puil, L., Lopert, R., Bero, L., Gnjidic, D., Sarpatwari, A. & Dormuth, C., 2022, In: Pharmacoepidemiology and Drug Safety. 31, S2, p. 76-76 1 p.

      Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

    4. Published

      Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study

      Morrow, R. L., Mintzes, B., Souverein, P. C., Hallgreen, Christine Erikstrup, Ahmed, B., Roughead, E. E., De Bruin, M. L., Kristiansen, S. B., Lexchin, J., Kemp-Casey, A., Sketris, I., Mangin, D., Pearson, S. A., Puil, L., Lopert, R., Bero, L., Gnjidic, D., Sarpatwari, A. & Dormuth, C. R., 2022, In: Drug Safety. 45, p. 623–638

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

      Abtahi, S., Pajouheshnia, R., Durán, C. E., Riera-Arnau, J., Gamba, M., Alsina, E., Hoxhaj, V., Andersen, M., Bartolini, C., Kristiansen, S. B., Brown, J., Hallgreen, C. E., Garcia-Poza, P., Gardarsdottir, H., Gini, R., Girardi, A., Holthuis, E., Huerta, C., Ibánez, L., Limoncella, G. & 8 others, Martín-Pérez, M., Paoletti, O., Roberto, G., Souverein, P., Swart, K. M. A., Wing, K., Sturkenboom, M. & Klungel, O., 2023, In: Drug Safety. 46, 7, p. 689-702

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      Impact of European Benefit-Risk reassessment procedures on drug prescribing practices in Denmark

      De Bruin, M. L. (., Hallgreen, Christine Erikstrup & Andersen, Morten, Aug 2019.

      Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

    7. Published

      Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study

      Sindahl, Per, Ofori-Asenso, R., Hallgreen, Christine Erikstrup, Kemp, K., Gardarsdottir, H. & Bruin, M. L. D., 2022, In: British Journal of Clinical Pharmacology. 88, 3, p. 1379-1384

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      Impact of the 2012 pharmacovigilance legislation on the harmonisation of DHPCS in the EU

      Olafsdottir, G., Bukhave, S. M., Kalligeros, G., Hallgreen, Christine Erikstrup & De Bruin, M. L., Aug 2018, p. 515-516.

      Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

    9. Published

      Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis

      Durán, C. E., Riera-Arnau, J., Abtahi, S., Pajouheshnia, R., Hoxhaj, V., Gamba, M., Alsina, E., Martin-Perez, M., Garcia-Poza, P., Llorente-Garcia, A., Gonzalez-Bermejo, D., Ibánez, L., Sabaté, M., Vidal, X., Ballarín, E., Sanfélix-Gimeno, G., Rodríguez-Bernal, C., Peiró, S., García-Sempere, A., Sanchez-Saez, F. & 22 others, Ientile, V., Ingrasciotta, Y., Guarneri, C., Tanaglia, M., Tari, M., Herings, R., Houben, E., Swart-Polinder, K., Holthuis, E., Huerta, C., Gini, R., Roberto, G., Bartolini, C., Paoletti, O., Limoncella, G., Girardi, A., Hyeraci, G., Andersen, Morten, Kristiansen, S. B., Hallgreen, Christine Erikstrup, Klungel, O. & Sturkenboom, M., 2023, In: Frontiers in Pharmacology. 14, 12 p., 1207976.

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Submitted

      Implementation of electronic distribution of Direct Healthcare Professional Communications (DHPCs) by the Danish Medicines Agency: A survey study of physicians’ experiences and preferences

      Sindahl, P., Møllebæk, Mathias, Gardarsdottir, H., De Bruin, M. L. (., Hallgreen, Christine Erikstrup & Clemmensen, M. H., 2023, (Submitted) In: Therapeutic Advances in Drug Safety.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 Next

    ID: 122745397